###begin article-title 0
Erythropoietin: A Potent Inducer of Peripheral Immuno/Inflammatory Modulation in Autoimmune EAE
###end article-title 0
###begin p 1
Conceived and designed the experiments: PD RY SC. Performed the experiments: PD RY YM WL WL. Analyzed the data: PD RY YM WL SC WL. Contributed reagents/materials/analysis tools: PD RY. Wrote the paper: PD RY YM WL.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 595 596 595 596 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 601 602 601 602 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 332 336 <span type="species:ncbi:10090">mice</span>
Beneficial effects of short-term erythropoietin (EPO) therapy have been demonstrated in several animal models of acute neurologic injury, including experimental autoimmune encephalomyelitis (EAE)-the animal model of multiple sclerosis. We have found that EPO treatment substantially reduces the acute clinical paralysis seen in EAE mice and this improvement is accompanied by a large reduction in the mononuclear cell infiltration and downregulation of glial MHC class II expression within the inflamed CNS. Other reports have recently indicated that peripherally generated anti-inflammatory CD4+Foxp3+ regulatory T cells (Tregs) and the IL17-producing CD4+ T helper cell (Th17) subpopulations play key antagonistic roles in EAE pathogenesis. However, no information regarding the effects of EPO therapy on the behavior of the general mononuclear-lymphocyte population, Tregs or Th17 cells in EAE has emerged.
###end p 3
###begin title 4
Methods and Findings
###end title 4
###begin p 5
###xml 251 256 251 256 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35&#8211;55</sub>
We first determined in vivo that EPO therapy markedly suppressed MOG specific T cell proliferation and sharply reduced the number of reactive dendritic cells (CD11c positive) in EAE lymph nodes during both inductive and later symptomatic phases of MOG35-55 induced EAE. We then determined the effect in vivo of EPO on numbers of peripheral Treg cells and Th17 cells. We found that EPO treatment modulated immune balance in both the periphery and the inflamed spinal cord by promoting a large expansion in Treg cells, inhibiting Th17 polarization and abrogating proliferation of the antigen presenting dendritic cell population. Finally we utilized tissue culture assays to show that exposure to EPO in vitro similarly downregulated MOG-specific T cell proliferation and also greatly suppressed T cell production of pro-inflammatory cytokines.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
Taken together, our findings reveal an important new locus whereby EPO induces substantial long-term tissue protection in the host through signaling to several critical subsets of immune cells that reside in the peripheral lymphatic system.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 136 139 136 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Sebzda1">[1]</xref>
###xml 141 144 141 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Baldwin1">[2]</xref>
###xml 311 314 311 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Kassiotis1">[3]</xref>
###xml 316 319 316 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Stockinger1">[4]</xref>
###xml 677 678 677 678 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 680 681 680 681 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 827 830 827 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Dong1">[5]</xref>
###xml 832 835 832 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Stockinger2">[6]</xref>
###xml 837 840 837 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Komiyama1">[7]</xref>
###xml 842 845 842 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Sutton1">[8]</xref>
###xml 847 850 847 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-FuruzawaCarballeda1">[9]</xref>
###xml 891 892 891 892 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 897 898 897 898 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1212 1216 1212 1216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Fontenot1">[10]</xref>
###xml 1218 1222 1218 1222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Reddy1">[11]</xref>
###xml 1224 1228 1224 1228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Kohm1">[12]</xref>
Most autoreactive T cells are negatively selected and eliminated during thymic development in a process called central T cell tolerance [1], [2]. However, the central selection process is often incomplete and autoreactive lymphocytes with pathogenic potential still circulate in the peripheral lymphoid tissues [3], [4]. When abnormally activated by "self" antigens or mimics, these autoreactive T cells may attack self-organs thereby participating in the development of autoimmune disorders. This fact is supported by the demonstrable ability to induce a variety of autoimmune diseases in rodents using appropriate immunization protocols. Th17 cells are a unique subset of CD4+ TH cells and recent studies suggest that Th17 cells have an important pathogenic role in T cell mediated autoimmune disease and tissue inflammation [5], [6], [7], [8], [9]. Another distinct T cell population (CD4+Foxp3+) called regulatory T cells (Tregs) has also attracted attention recently because it plays an important role in maintenance of peripheral tolerance and in controlling the destructive self-reactive T cells found in autoimmune animal models of arthritis, multiple sclerosis, diabetes, and inflammatory bowel disease [10], [11], [12]. Modulating the Treg population and other associated factors may prove to be an effective new therapy for autoimmune disease.
###end p 9
###begin p 10
###xml 130 134 130 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Wekerle1">[13]</xref>
###xml 136 140 136 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Li1">[14]</xref>
###xml 459 463 459 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Johnson1">[15]</xref>
###xml 465 469 465 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Steinman1">[16]</xref>
###xml 471 475 471 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Ford1">[17]</xref>
###xml 477 481 477 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Sun1">[18]</xref>
###xml 658 662 658 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Sun1">[18]</xref>
###xml 664 668 664 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Sun2">[19]</xref>
###xml 851 855 851 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Chitnis1">[20]</xref>
###xml 857 861 857 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Hofstetter1">[21]</xref>
###xml 863 867 863 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Ponomarev1">[22]</xref>
###xml 609 613 <span type="species:ncbi:10090">mice</span>
###xml 625 629 <span type="species:ncbi:10090">mice</span>
EAE is a central nervous system inflammatory demyelinating disease of animals that attacks the spinal cord and brain white matter [13], [14]. The CNS white matter histopathology in EAE animals is similar to that in multiple sclerosis (MS) in that there are prominent white matter perivascular infiltrating T cells, myelin destruction and associated axonal damage. Autoreactive CD4 and CD8 T cells are believed to be involved in the pathogenesis of EAE and MS [15], [16], [17], [18]. Subcutaneous injection of myelin antigen into animals or adoptive transfer of purified MOG-specific T cells obtained from EAE mice into naive mice can both induce the disease [18], [19]. Proinflammatory cytokines, especially IL-2 and TNF-alpha have been demonstrated to play a significant role in both the induction phase and later clinical stages of EAE pathogenesis [20], [21], [22].
###end p 10
###begin p 11
###xml 258 262 258 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Li1">[14]</xref>
###xml 264 268 264 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Brines1">[23]</xref>
###xml 270 274 270 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Agnello1">[24]</xref>
###xml 276 280 276 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Grasso1">[25]</xref>
###xml 559 563 559 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Li1">[14]</xref>
###xml 119 125 <span type="species:ncbi:9606">humans</span>
Erythropoietin (EPO), a 165 amino acid glycoprotein cytokine, has been used extensively for the treatment of anemia in humans and has been shown to have the capacity to induce neuroprotection in a disparate variety of animal models of nervous system disease [14], [23], [24], [25]. We have previously demonstrated that EPO therapy is of substantial clinical benefit and EPO treatment significantly reduces mononuclear cell infiltration, downregulates MHC class II expression, and induces axonal protection within the brain and spinal cord of animals with EAE [14].
###end p 11
###begin p 12
###xml 288 293 <span type="species:ncbi:10090">mouse</span>
The mechanism by which EPO induces neuroprotection in EAE remains unclear. In this study, we characterized the effect of EPO on immunogenesis within the peripheral lymphoid tissues and the impact of EPO therapy on infiltrating inflammatory cells within the CNS target organ using the EAE mouse model. We found that EPO therapy exerts unexpectedly profound biologic effects within the peripheral lymphoid system tissues and acts as a potent molecular check on inflammation by blocking dendritic cell expansion and T cell proliferation while inducing rapid expansion of the Treg cell population and a corresponding reduction in Th17 cells. This comprehensive immune modulating mechanism likely accounts for the bulk of the EPO neuroprotective effects induced in the EAE animal model.
###end p 12
###begin title 13
Results
###end title 13
###begin title 14
EPO down-regulates MOG-specific T cell proliferation in vitro and suppresses T cell cytokine production
###end title 14
###begin p 15
###xml 126 131 126 131 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">40&#8211;54</sub>
###xml 139 144 139 144 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">44&#8211;54</sub>
###xml 186 187 186 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 258 262 258 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Sun2">[19]</xref>
###xml 329 334 329 334 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35&#8211;55</sub>
###xml 487 492 487 492 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">44&#8211;54</sub>
###xml 497 498 497 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 506 513 506 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001924-g001">Fig. 1a</xref>
###xml 583 588 583 588 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35&#8211;55</sub>
###xml 640 645 640 645 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">44&#8211;54</sub>
###xml 650 651 650 651 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 701 708 701 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001924-g001">Fig. 1a</xref>
###xml 784 791 784 791 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">366&#8211;374</sub>
###xml 796 797 796 797 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 853 860 853 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001924-g001">Fig. 1a</xref>
###xml 345 349 <span type="species:ncbi:10090">mice</span>
###xml 427 432 <span type="species:ncbi:10090">mouse</span>
###xml 607 611 <span type="species:ncbi:10090">mice</span>
###xml 957 961 <span type="species:ncbi:10090">mice</span>
###xml 1002 1007 <span type="species:ncbi:10090">mouse</span>
Autoreactive T cells are believed to play key roles in the pathogenesis of EAE. Two major pathogenic MOG peptide epitopes (MOG40-54 and MOG44-54) have been used to construct peptide/H-2Db dimeric complexes to quantify the encephalitogenic CD8 T cell subsets [19]. We first determined if peripheral MOG-specific CD8 T cells in MOG35-55 immunized mice could be quantified by flow cytometry. As expected, less than 0.5% of normal mouse spleen mononuclear cells stained positive with the MOG44-54/H-2Db dimer (Fig. 1a). By contrast, about 3% of spleen mononuclear cells obtained from MOG35-55 peptide immunized mice were double positive for MOG44-54/H-2Db dimer and CD8 staining 7 days post immunization (Fig. 1a). In contrast, we found less than 0.6% non-specific binding to a control NP366-374/H-2Db dimer by the same EAE splenic single-cell suspensions (Fig. 1a). Adoptive transfer of these EAE-MOG induced T cells generated clinical EAE in naive normal C57 mice and CNS pathologic changes in recipient mouse spinal cords about 14 days after adoptive transfer (data not shown).
###end p 15
###begin title 16
EPO down-regulates proliferation of MOG-specific T cells and suppresses T cell cytokine production.
###end title 16
###begin p 17
###xml 152 157 152 157 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">44&#8211;54</sub>
###xml 254 259 254 259 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">44&#8211;54</sub>
###xml 318 323 318 323 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">44&#8211;54</sub>
###xml 395 400 395 400 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35&#8211;55</sub>
###xml 557 564 557 564 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">366&#8211;374</sub>
###xml 890 895 890 895 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">44&#8211;54</sub>
###xml 1215 1220 1215 1220 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">44&#8211;54</sub>
###xml 205 209 <span type="species:ncbi:10090">mice</span>
a) Single cell suspensions of hyperimmune EAE spleen were prepared 7 days post MOG peptide immunization and quantified by flow cytometry for CD8 and MOG44-54/H-2Db dimer double positive binding. In normal mice, 0.42% of splenic CD8 cells bound to the MOG44-54/H-2Db dimer (left side), whereas an 8-fold increase in MOG44-54/H-2Db dimer positive staining occurred in CD8 T cells obtained from MOG35-55 immunized EAE animals (middle). In contrast, when a non-specific control peptide was tested, only 0.6% of CD8 cells exhibited non-specific binding to the NP366-374 dimer (right). b & c) MOG-EAE antigen specific T cells were enriched by exposure to antigen in long term tissue culture, and then exposed to EPO (1 or 10 U/ml) for 72 hrs. Supernatants were collected from the cultured MOG-T cells for cytokine profile analysis and the remaining cells were quantified for number of CD8 and MOG44-54/H-2Db dimer double binding cells after exposure to EPO or control treatment. EPO induced a marked decrease in pro-inflammatory cytokine production (black bars) when compared to controls (white bars). EPO at 1 U/ml induced a substantial decline in the MOG-specific CD8 T cell population (c-middle panel). Some of the MOG44-54-peptide/H-2Db dimer positive, non-CD8 T cell (including portion of CD11c positive cells) populations were also reduced by EPO treatment (c-middle panel). Each data point is the mean+/-SEM of three experiments performed in triplicate. *, p<0.005.
###end p 17
###begin p 18
###xml 562 569 554 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001924-g001">Fig. 1b</xref>
###xml 698 705 690 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001924-g001">Fig. 1b</xref>
###xml 914 921 906 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001924-g001">Fig. 1c</xref>
To determine whether EPO exerted a direct effect on MOG-specific T cells and their cytokine profile, we enriched EAE MOG-specific T cells in long term culture and then treated them with EPO (1, 10,100 U/ml) for 48-72 hrs. Culture supernatants were collected for cytokine quantification and the remaining cell population was reacted with peptide/dimer complexes and anti-CD8 antibody to determine the number of MOG specific T cells. EPO (1 U/ml) induced a substantial reduction (*p<0.005) in major pro-inflammatory cytokines (IL-6, TNF-alpha, IL-2 and IFNgamma) (Fig. 1b). A mild reduction in level of GM-CSF (p = 0.09) and insignificant changes in IL-4, IL-10, IL-5 and IL-12 levels were observed (Fig. 1b). We also found a marked reduction in numbers of MOG antigen specific T cells in EPO treated samples (p<0.005) and this correlated well with the marked reduction in multiple pro-inflammatory cytokine levels (Fig. 1c). The EPO-mediated downregulation of MOG-specific T cell proliferation was dose related and the most effective reductions were observed in lower dose EPO treated samples (1 and 10 U/ml), whereas high dose EPO (100 U/ml) in cell culture had little effect on numbers of MOG-T cells and levels of cytokine (data not shown).
###end p 18
###begin title 19
EPO treatment reduces inflammatory mononuclear cell (MNC) numbers in peripheral lymph nodes
###end title 19
###begin p 20
###xml 182 186 182 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Li1">[14]</xref>
###xml 300 305 300 305 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35&#8211;55</sub>
###xml 395 399 395 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Brines1">[23]</xref>
###xml 401 405 401 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Grasso1">[25]</xref>
###xml 933 940 933 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001924-t001">Table 1</xref>
###xml 1500 1507 1500 1507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001924-g002">Fig. 2a</xref>
###xml 1598 1603 1598 1603 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">44&#8211;54</sub>
###xml 1706 1713 1706 1713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001924-g002">Fig. 2b</xref>
###xml 177 181 <span type="species:ncbi:10090">mice</span>
###xml 537 541 <span type="species:ncbi:10090">mice</span>
###xml 679 683 <span type="species:ncbi:10090">mice</span>
###xml 1034 1038 <span type="species:ncbi:10090">mice</span>
###xml 1700 1704 <span type="species:ncbi:10090">mice</span>
We previously reported that both disease severity and duration of maximum impairment were reduced when EPO therapy was initiated after onset of neurologic impairment in MOG-EAE mice [14]. Others have reported that early EPO treatment during the EAE induction period (prior to or immediately after MOG35-55 immunization) was also effective in delaying disease onset and reducing disease severity [23], [25]. To assess if EPO treatment post MOG-immunization had direct immunomodulating effects within the peripheral lymphoid tissue of EAE mice, EPO or sham PBS treatment was initiated 7 days post immunization and draining inguinal lymph nodes (DILNs) from EPO or sham treated EAE mice were subsequently obtained at different time points. The total number of MNCs, CD4, CD8 T cells and CD11c positive dendritic cells as well as MHC class I and class II expression on the DILN cells was quantified by flow cytometry at different times. Table 1 shows a greatly expanded inflammatory mononuclear cell population occurs in sham treated EAE mice on day 11 post MOG-immunization compared to normal controls and the inflammatory cell subset numbers also remained higher than normal on day 17. EPO treatment for as few as 3 days (day 11 post MOG-immunization) significantly reduced all subsets of the inflammatory cells (p<0.001) and a similar reduction in cell subsets was observed on day 17. We also found that EPO treatment for 3 days down-regulated MHC class I and II expression in DILN mononuclear cells (Fig. 2a, p<0.001). About 4.0% of the spleen mononuclear cells were double positive for CD3 and MOG44-54 dimer binding and EPO treatment significantly reduced the MOG-specific T cell population in EAE mice (Fig. 2b, p<0.01).
###end p 20
###begin title 21
In vivo effect of EPO treatment on MHC expression and number of MOG antigen specific T cells in inguinal lymph nodes.
###end title 21
###begin p 22
###xml 56 61 56 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35&#8211;55</sub>
###xml 516 521 516 521 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">44&#8211;54</sub>
###xml 664 669 664 669 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">40&#8211;54</sub>
###xml 39 43 <span type="species:ncbi:10090">mice</span>
###xml 143 147 <span type="species:ncbi:10090">mice</span>
###xml 409 413 <span type="species:ncbi:10090">mice</span>
###xml 461 466 <span type="species:ncbi:10090">mouse</span>
###xml 622 626 <span type="species:ncbi:10090">mice</span>
EPO treatment was started 7 days after mice received MOG35-55 immunization. Bilateral draining inguinal lymph nodes (DILNs) were obtained from mice on day 11 (after 3 day treatment with either EPO at 5000 U/kg/day or sham treatment with PBS) and single cell suspensions were prepared. a) EPO treatment down-regulated mononuclear cell MHC class I (left) and class II (right) expression in lymph nodes from EAE mice. b) Less than 0.7% of single cells from normal mouse inguinal lymph nodes were double-positive for MOG44-54 dimer and anti-CD3 antibody. In contrast, about 4% of single cell suspensions from sham treated EAE mice were positive for FITC-CD3 and PE-MOG40-54/H-2Db dimer double staining (middle), whereas EPO treatment reduced in vivo proliferation of MOG-specific T cells back to 1.5% (right).
###end p 22
###begin title 23
EPO reduces total number of Mononuclear and T cells in EAE lymph nodes
###end title 23
###begin p 24
###xml 133 134 133 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 147 148 147 148 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 87 91 <span type="species:ncbi:10090">Mice</span>
###xml 204 208 <span type="species:ncbi:10090">mice</span>
EPO or sham PBS daily treatment for 3 days was initiated 7 days post MOG-immunization. Mice (n = 6/group) were sacrificed on day 11 (a) or day 17 (b). DILNs were harvested for cell quantification. Normal mice (n = 6) were used as controls.
###end p 24
###begin p 25
mean+/-SEM
###end p 25
###begin p 26
###xml 55 59 <span type="species:ncbi:10090">mice</span>
p<0.001 (sham PBS treated EAE vs NL or EPO-treated EAE mice)
###end p 26
###begin p 27
###xml 35 39 <span type="species:ncbi:10090">mice</span>
p<0.05 (sham PBS treated EAE vs NL mice)
###end p 27
###begin p 28
###xml 221 226 221 226 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35&#8211;55</sub>
###xml 480 487 480 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001924-g003">Fig. 3a</xref>
###xml 929 936 929 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001924-g003">Fig. 3b</xref>
###xml 1011 1018 1011 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001924-g003">Fig. 3c</xref>
###xml 153 157 <span type="species:ncbi:10090">mice</span>
###xml 193 197 <span type="species:ncbi:10090">Mice</span>
###xml 465 469 <span type="species:ncbi:10090">mice</span>
###xml 633 637 <span type="species:ncbi:10090">mice</span>
###xml 697 701 <span type="species:ncbi:10090">mice</span>
###xml 872 876 <span type="species:ncbi:10090">mice</span>
###xml 905 909 <span type="species:ncbi:10090">mice</span>
###xml 923 927 <span type="species:ncbi:10090">mice</span>
We next determined if EPO had similar immunomodulating effects on the peripheral lymphoid tissues when EPO treatment was started at the same time as the mice received MOG peptide immunization. Mice were immunized with MOG35-55 and then divided randomly into two groups that received either immediate EPO treatment (5000 U/kg/day x3 followed by 1000 U/kg/dayx3) or PBS sham treatment over the same period for a total of 6 days. DILNs and spleens were collected from mice on day 7. Fig. 3a shows greatly enlarged DILNs were induced in sham treated MOG-EAE by 7 days post immunization. In contrast, the size of DILNs in EPO treated EAE mice was much smaller and resembled lymphoid tissue from normal mice. When total mononuclear cells were quantified from single cell suspensions of harvested inguinal lymph nodes, we again found much higher cell numbers in sham treated EAE mice compared to EPO treated EAE mice or to normal mice (Fig. 3b). EPO therapy significantly reduced the population of CD11c positive DCs (Fig. 3c) and the numbers of CD4, CD8 T cells (data not shown).
###end p 28
###begin title 29
Early EPO treatment sharply reduced total numbers of inflammatory cells and limited expansion of the dendritic cell population in DILNs during the EAE induction phase.
###end title 29
###begin p 30
###xml 4 8 <span type="species:ncbi:10090">mice</span>
###xml 228 232 <span type="species:ncbi:10090">mice</span>
###xml 300 304 <span type="species:ncbi:10090">mice</span>
###xml 596 600 <span type="species:ncbi:10090">mice</span>
###xml 611 615 <span type="species:ncbi:10090">mice</span>
###xml 840 844 <span type="species:ncbi:10090">mice</span>
###xml 933 937 <span type="species:ncbi:10090">mice</span>
C57 mice received EPO or PBS sham treatment starting on the day of MOG-immunization for 6 days and lymph nodes were obtained on day 7. a) Significantly enlarged inguinal lymph nodes were observed in control sham treated MOG-EAE mice (middle), whereas much smaller nodes were found in EPO treated EAE mice (right) similar in size to nodes from normal animals (left). b) Total MNCs were quantified from single cell suspensions of DILNs after lysis of RBCs. Greatly increased inflammatory mononuclear cell numbers were observed in sham treated EAE lymph nodes compared to DILNs from EPO treated EAE mice or normal mice. c) Cells were reacted with fluorophore labeled mAbs specific for surface markers (MHC class II and CD11c) and analyzed by flow cytometry. Note that the large expansion in dendritic cell population found in sham treated EAE mice was dramatically suppressed by EPO therapy. Data represents mean+/-SEM for 6 individual mice. **, p<0.0001.
###end p 30
###begin title 31
###xml 98 102 <span type="species:ncbi:10090">mice</span>
EPO treatment induces peripheral Treg cell expansion and blocks Th17 cell polarization in MOG-EAE mice
###end title 31
###begin p 32
###xml 313 320 313 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001924-g004">Fig. 4a</xref>
###xml 532 536 532 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Zheng1">[26]</xref>
###xml 538 542 538 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Hofstetter2">[27]</xref>
###xml 544 548 544 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Kim1">[28]</xref>
###xml 550 554 550 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Suryani1">[29]</xref>
###xml 1047 1056 1047 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001924-g004">Fig. 4b&#8211;c</xref>
###xml 1146 1155 1146 1155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001924-g004">Fig. 4b&#8211;c</xref>
###xml 156 160 <span type="species:ncbi:10090">mice</span>
Brief treatment with EPO during the EAE induction period for 6 days significantly delayed onset of clinical neurologic deficit compared to sham treated EAE mice (P<0.05). This brief course of EPO treatment induced a neuroprotective effect that was sustained over a long term clinical follow-up period of 45 days (Fig. 4a). Both Treg and Th17 cells are believed to be critical for control of the autoimmune inflammatory process in EAE and other autoimmune diseases including collagen-induced arthritis and inflammatory bowel disease [26], [27], [28], [29]. We suspected that EPO-mediated neuroprotection in EAE might be in part a consequence of an immunomodulating effect on the balance of Treg and Th17 cell populations in either peripheral lymphoid tissue or the central nervous system target organ. We found a significant reduction in the number of peripheral Treg cells and a remarkable increase in peripheral Th17 cells during the early symptomatic phase (day 16 post MOG-immunization) in sham treated EAE animals compared to normal controls (Fig. 4b-c). EPO treatment for 6 days induced significant expansion in Treg cells within the DILNs (Fig. 4b-c) and significantly reduced the polarization of Th17 cells in the periphery.
###end p 32
###begin title 33
EPO induced sustained immuno/inflammatory modulation by expanding peripheral Treg cell numbers and reducing Th17 positive cells.
###end title 33
###begin p 34
###xml 539 540 535 536 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 545 546 541 542 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 217 221 <span type="species:ncbi:10090">mice</span>
###xml 267 271 <span type="species:ncbi:10090">mice</span>
###xml 342 346 <span type="species:ncbi:10090">mice</span>
###xml 405 409 <span type="species:ncbi:10090">mice</span>
###xml 441 445 <span type="species:ncbi:10090">mice</span>
###xml 643 648 <span type="species:ncbi:10090">mouse</span>
###xml 756 760 <span type="species:ncbi:10090">mice</span>
###xml 1057 1061 <span type="species:ncbi:10090">mice</span>
Mice were immunized with MOG and received daily EPO treatment for 6 days (day1-6). a). EPO therapy for 6 days delayed onset of clinical neurologic signs in animals and reduced the magnitude of clinical deficit in EAE mice (*) compared to sham treated control (o) EAE mice (*, p<0.05). The clinical score was determined as the mean+/-SEM of 8 mice per group. Data represents the mean+/-SEM of 8 individual mice. b-c) DILNs were obtained from mice after 6 days treatment with either EPO or PBS. Cells were quantified for number of Tregs (CD4+Foxp3+) and Th17 by flow cytometry. Panel b shows that about 3.4% Treg cells were detectable in normal mouse inguinal lymph node (left). A reduced number (2.4%) of Treg cells was detected in sham treated EAE control mice nodes (middle), whereas EPO therapy induced a 2-fold increase in Foxp3+ Treg cells on day 16 compared to sham treatment (right). Panel c shows <0.2% of normal healthy lymph node cells stained positive for Th17 (left). Numbers of peripheral Th17 cells greatly increased on day 16 (15-fold) in EAE mice treated with PBS (middle, 3.2%). In marked contrast, EPO therapy (right) sharply reduced the number of peripheral Th17 cells in MOG-immunized animals.
###end p 34
###begin p 35
###xml 50 55 50 55 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">40&#8211;54</sub>
###xml 817 824 817 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001924-g005">Fig. 5a</xref>
###xml 1090 1097 1090 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001924-g005">Fig. 5b</xref>
###xml 1431 1436 1431 1436 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">40&#8211;54</sub>
###xml 1553 1560 1553 1560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001924-g005">Fig. 5c</xref>
###xml 1650 1655 1650 1655 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">40&#8211;54</sub>
###xml 172 176 <span type="species:ncbi:10090">mice</span>
###xml 1039 1043 <span type="species:ncbi:10090">mice</span>
###xml 1770 1774 <span type="species:ncbi:10090">mice</span>
To serially quantify the Tregs, Th17 cells and MOG40-54-specific T cells in EAE animals after treatment with either EPO or sham PBS, fresh MNCs from DILNs of MOG-immunized mice were obtained at different time points after initiation of either EPO or sham PBS treatment. We found sustained reductions in Treg cells during the early EAE induction period, the symptomatic phase as well as the late chronic phase in sham treated EAE animals compared to normal controls (p<0.01). The reduction in peripheral Treg cells in sham treated EAE was more apparent on day 7 (before onset of clinical signs) and on day 16 (early acute clinical disease) than later in the disease course. EPO treatment induced a significant expansion in Treg cells within the peripheral lymphoid tissue that could be detected at a very early stage (Fig. 5a). The increased number of peripheral Tregs was even more prominent 5 weeks after termination of EPO treatment (p<0.001). The Th17 cell population in peripheral lymphoid tissue remained elevated in sham treated EAE mice during both the early and late stages of EAE (Fig. 5b), as expected. The Th17 expansion was associated with a fulminant inflammatory response following MOG-immunization in untreated EAE animals and was associated with severe clinical disease. EPO therapy significantly blocked polarization of peripheral Th17 cells (p<0.001). In addition, early EPO treatment again reduced peripheral MOG40-54/H-2Db antigen specific T cells while inducing sustained suppression of the MOG-T effector cell population (p<0.001, Fig. 5c). The expansion in peripheral Treg cells, and marked reduction in peripheral Th17 and MOG40-54/H-2Db specific T cells as well as the abrogation of dendritic cell proliferation that occurred in EPO treated EAE mice clearly correlated well with less severe clinical disease.
###end p 35
###begin title 36
EPO treatment induced peripheral Treg cell expansion while reducing MOG-specific T cells and Th17 positive cells in peripheral lymphoid tissues.
###end title 36
###begin p 37
###xml 277 278 277 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 283 284 283 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 792 797 792 797 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">40&#8211;54</sub>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 183 187 <span type="species:ncbi:10090">mice</span>
###xml 419 423 <span type="species:ncbi:10090">mice</span>
###xml 635 639 <span type="species:ncbi:10090">mice</span>
###xml 869 873 <span type="species:ncbi:10090">mice</span>
###xml 919 923 <span type="species:ncbi:10090">mice</span>
Mice were immunized with MOG and received daily EPO treatment for 6 days (day1-6). DILNs and spinal cords were obtained at three different time points (day 7, day 16 and day 45) from mice treated with EPO or sham treated with PBS. Cells were quantified for number of Tregs (CD4+Foxp3+), Th17 and MOG-antigen specific T cells by flow cytometry. a) There were reduced numbers of Treg cells in DILNs from sham treated EAE mice at early stages (day 7) as well as at the peak of clinical signs (d16), and during recovery (day 45) compared to normal healthy control animals. b) Numbers of peripheral Th17 cells increased in sham treated EAE mice, whereas EPO therapy sharply reduced the number of peripheral Th17 cells in MOG-immunized animals. c) EPO treatment significantly reduced peripheral MOG40-54/H-2Db specific T effector cell population compared to sham treated EAE mice. Data represents mean+/-SEM for 6 individual mice. *, p<0.05; **, p<0.001.
###end p 37
###begin title 38
###xml 91 96 <span type="species:ncbi:10090">mouse</span>
EPO treatment increased numbers of Treg cells and reduced numbers of Th17 cells in MOG-EAE mouse spinal cord
###end title 38
###begin p 39
###xml 659 666 659 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001924-g006">Fig. 6a</xref>
###xml 875 882 875 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001924-g006">Fig. 6a</xref>
###xml 1080 1081 1080 1081 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1126 1138 1126 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001924-g006">Fig. 6 (b&#8211;c)</xref>
###xml 1238 1245 1238 1245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001924-g006">Fig. 6b</xref>
###xml 1277 1284 1277 1284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001924-g006">Fig. 6c</xref>
###xml 155 159 <span type="species:ncbi:10090">mice</span>
###xml 280 284 <span type="species:ncbi:10090">mice</span>
###xml 378 382 <span type="species:ncbi:10090">mice</span>
During the EAE induction phase, we found increased numbers of inflammatory cells within spinal cords shortly before onset of paralysis in sham treated EAE mice (about day 7-10), In contrast far fewer infiltrating inflammatory cells were found in spinal cords from EPO treated EAE mice. The number of CNS infiltrating inflammatory cells was 4-5 times greater in sham treated EAE mice compared to EPO treated animals when animals were studied either at their peak clinical neurologic deficit or at later stages of EAE (day 45). Detailed analysis of the inflammatory cells infiltrating the CNS again revealed higher numbers of Treg cells in EPO treated animals (Fig. 6a). The increased Treg cell population in the diseased CNS similarly became more evident in late stages of the disease, suggesting that Treg cells continue to migrate into the CNS for a lengthy period of time (Fig. 6a). The increased number of anti-inflammatory Treg cells infiltrating the spinal cord in EPO-treated EAE animals was confirmed by direct immunohistochemical staining for Treg cells (mAb against Foxp3+) on paraffin-embedded spinal cord sections. Fig. 6 (b-c) shows a substantial increase in infiltrating Treg cells within the spinal cord of EPO-treated EAE (Fig. 6b) compared to sham treated EAE (Fig. 6c).
###end p 39
###begin title 40
###xml 91 96 <span type="species:ncbi:10090">mouse</span>
EPO treatment increased numbers of Treg cells and reduced numbers of Th17 cells in MOG-EAE mouse spinal cord.
###end title 40
###begin p 41
###xml 256 257 256 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 262 263 262 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 574 575 574 575 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 18 22 <span type="species:ncbi:10090">mice</span>
###xml 162 166 <span type="species:ncbi:10090">mice</span>
###xml 944 949 <span type="species:ncbi:10090">mouse</span>
###xml 1308 1312 <span type="species:ncbi:10090">mice</span>
MOG-immunized C57 mice received daily EPO or PBS treatment for 6 days (day 1-6). Spinal cords were obtained at two different time points (day 16 and day 45) from mice treated with EPO or sham treated with PBS. Cells were quantified for number of Tregs (CD4+Foxp3+), Th17 and MOG-antigen specific T cells by flow cytometry. a) EPO therapy induced a substantial increase in Foxp3+ Treg cells in EAE spinal cords. The EPO induced expansion of Tregs in the CNS became even more evident in late stages of the disease and correlated with less severe neurologic deficit. b-c) Foxp3+ labeled Treg cells in PBS or EPO treated MOG-EAE spinal cord by IHC. Panel b shows a sham treated EAE spinal cord section reacted with Foxp3 antibody containing few labeled cells. By contrast, many more Foxp3+ cells were present in the infiltrates of EPO treated EAE spinal cord (panel c). d) Significantly increased numbers of Th17 cells occurred in sham treated EAE mouse spinal cord and this correlated with more severe clinical neurologic deficits whereas EPO therapy suppressed the number of spinal cord Th17 cells. e) Increased MOG antigen-specific T cells occurred within untreated EAE spinal cord, and EPO induced large reductions in MOG-specific T effector cells within the CNS. Data represents mean+/-SEM for 6 individual mice. *, p<0.05; **, P<0.001.
###end p 41
###begin p 42
###xml 311 318 311 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001924-g006">Fig. 6d</xref>
###xml 552 559 552 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001924-g006">Fig. 6e</xref>
Significantly increased Th17 cells within the CNS were found at the time animals developed clinical disease, and higher numbers of Th17 cells in spinal cords were notably associated with more severe clinical neurologic deficits in EAE animals. EPO treatment reduced infiltrating Th17 cells in the diseased CNS (Fig. 6d) as previously described in peripheral lymph nodes. Similarly, a marked reduction in MOG-T effector cells within the CNS as judged by the antigen dimer assay was observed in EPO treated animals compared to sham treated EAE controls (Fig. 6e).
###end p 42
###begin title 43
Discussion
###end title 43
###begin p 44
###xml 273 277 273 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Steinman1">[16]</xref>
###xml 279 283 279 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Goverman1">[30]</xref>
###xml 285 289 285 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Huseby1">[31]</xref>
###xml 422 426 422 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Li1">[14]</xref>
###xml 786 790 <span type="species:ncbi:10090">mice</span>
EAE is a commonly studied animal model of acute central nervous system inflammatory demyelinating disease, and it is believed that autoreactive T cells and proinflammatory cytokines play key roles in the early inductive phase and later paralytic stages of EAE pathogenesis [16], [30], [31]. We have previously demonstrated that EPO treatment blocks clinical progression and blunts the disease pathology in MOG-induced EAE [14]. In this study, we utilized in vitro and ex vivo methods to explore potential mechanisms by which EPO mediates neuroprotection in the EAE animal model. We found in vitro that exposure of enriched EAE splenic T cell cultures to EPO significantly downregulated autoreactive T cell numbers and their production of proinflammatory cytokines. EPO treatment in EAE mice also greatly reduced total MNC numbers in lymphoid system tissue, including the antigen presenting DC population as well as T cells. Most importantly, EPO treatment also resulted in a marked expansion in the Treg cell population and a corresponding reduction in Th17 cells and MOG-specific T cells within both peripheral lymphoid tissue and diseased EAE spinal cords. By modulating multiple functional immune cell types and their corresponding cytokines, EPO therapy transformed a significantly destabilized autoimmune process in EAE animals into one of relatively normal immune status. As a consequence, less severe neurologic deficits and less neuropathologic abnormalities were found in EPO treated EAE animals compared to sham treated controls.
###end p 44
###begin p 45
###xml 217 221 217 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Steinman1">[16]</xref>
###xml 223 227 223 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Ford1">[17]</xref>
###xml 229 233 229 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Sun1">[18]</xref>
###xml 235 239 235 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Goverman1">[30]</xref>
###xml 370 374 370 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Goverman1">[30]</xref>
###xml 376 380 376 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-McDole1">[32]</xref>
###xml 430 435 430 435 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35&#8211;55</sub>
###xml 566 571 566 571 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">40&#8211;54</sub>
###xml 623 627 623 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Sun2">[19]</xref>
###xml 866 871 866 871 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">44&#8211;54</sub>
###xml 876 877 876 877 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 1118 1122 1118 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Li1">[14]</xref>
###xml 252 257 <span type="species:ncbi:9606">human</span>
###xml 329 334 <span type="species:ncbi:9606">human</span>
###xml 1087 1092 <span type="species:ncbi:10090">mouse</span>
Traditionally CD4 T cells have been considered to be the critical element in EAE pathogenesis, but recent studies have indicated that CD8 cells may also play an important role in EAE induction and disease progression [16], [17], [18], [30]. Studies on human CNS tissue also support the notion that myelin-specific CD8 T cells in human MS lesions may be encephalitogenic [30], [32]. A truncated MOG peptide library derived from MOG35-55 has been previously used to identify the key peptide epitopes for pathogenic T cells and two major MOG peptide epitopes within MOG40-54 have been found to be pathogenic for EAE induction [19]. To determine if EPO had a direct impact on MOG-specific T cells and their associated cytokines, we studied MOG-specific T cells in culture after exposure to EPO or medium alone. Low dose EPO significantly reduced the proliferation of MOG44-54/H-2Db specific CD8 T cells, while much higher doses (100 U/ml) had only minor or no effect. A similar J-shaped dose-response curve following EPO exposure has been previously observed in MHC class II expression on a mouse EOC microglial cell line [14].
###end p 45
###begin p 46
###xml 113 117 109 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Chitnis1">[20]</xref>
###xml 119 123 115 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Hofstetter1">[21]</xref>
###xml 125 129 121 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Ponomarev2">[33]</xref>
###xml 448 453 444 449 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">44&#8211;54</sub>
Since proinflammatory cytokines, especially IL-2, IL-6 and TNF-alpha, play significant roles in EAE pathogenesis [20], [21], [33], we collected supernatants from either EPO or control media treated cell cultures and quantified levels of cytokines. Exposure to EPO induced substantial reductions in all of the major classic pro-inflammatory cytokines and the reduced cytokine level in EPO treated samples was associated with decreased numbers of MOG44-54 dimer positive pathogenic T cells. There were no significant alterations in Th2-type cytokines such as IL-4 and IL-5 in EPO treated samples compared to controls. The in vitro EPO-mediated reduction in proinflammatory cytokines was also dose dependent.
###end p 46
###begin p 47
###xml 333 337 333 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Kohm1">[12]</xref>
###xml 339 343 339 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-FernandezMartin1">[34]</xref>
###xml 345 349 345 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Sakaguchi1">[35]</xref>
###xml 351 355 351 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Reddy2">[36]</xref>
###xml 357 361 357 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Bynoe1">[37]</xref>
###xml 363 367 363 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Viglietta1">[38]</xref>
###xml 1360 1364 1360 1364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-FernandezMartin1">[34]</xref>
###xml 552 556 <span type="species:ncbi:10090">mice</span>
The EPO-mediated non-specific and specific immune modulating effects on peripheral lymphoid tissues in EPO-treated EAE animals likely contributes to their less severe clinical course. Anti-inflammatory regulatory T cells have been found to be an important CD4 cell subpopulation for controlling the development of autoimmune disease [12], [34], [35], [36], [37], [38]. Adoptive transfer of Treg cells has been shown to be of therapeutic efficacy in several animal autoimmune disease models. Our study shows that short-term EPO therapy in MOG-immunized mice is associated with rapid expansion of the Treg cell population in peripheral lymphoid tissue and this EPO-induced expansion of Treg cells was sustained over long term follow up. In fact, EPO-treated EAE animals that manifested delayed onset of clinical disease and less neurologic damage were found to have higher numbers of Treg cells within both DILNs and spinal cord. The EPO-induced higher Treg population may play an important role in reducing the peripheral immune response to MOG autoantigen, and may be the major source of Tregs migrating into CNS to minimize inflammation within CNS white matter. A recent study showed that anti-inflammatory vasoactive intestinal peptide also prevents neurologic progression in MOG-EAE by inducing Treg cell expansion in peripheral lymphoid tissue and the CNS [34].
###end p 47
###begin p 48
###xml 401 406 401 406 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35&#8211;55</sub>
###xml 539 543 539 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Hofstetter3">[39]</xref>
###xml 569 574 569 574 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">40&#8211;54</sub>
###xml 276 281 <span type="species:ncbi:9606">human</span>
###xml 419 423 <span type="species:ncbi:10090">mice</span>
###xml 534 538 <span type="species:ncbi:10090">mice</span>
The other important subpopulation of CD4 helper T cells recently recognized to be a critical player in inflammatory autoimmune disease pathogenesis is the IL-17 cell. IL-17 is a potent proinflammatory cytokine and overproduction of IL-17 has been associated with a variety of human autoimmune diseases and their corresponding animal models. The kinetics and organ distribution of Th17 cells in our MOG35-55 induced EAE mice was very similar to the Th17 cell kinetics following proteolipid protein 139-151 peptide induced EAE in SLJ/J mice [39]. Th17 cells, like the MOG40-54 specific T cells, reside mainly in the peripheral lymphatics during the EAE induction phase after immunization. Later, when increased numbers of infiltrating inflammatory cells invade the CNS (12-20 days post MOG-immunization), Th17 cells, together with MOG-specific T effector cells, were easily detected in diseased spinal cords. EPO treatment abrogates the proliferation of peripheral Th17 cells during both the early induction phase as well as at later stages of EAE, and EPO treatment inhibits Th17 cell formation within the spinal cord during both acute and convalescent phases of EAE.
###end p 48
###begin p 49
###xml 334 338 334 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Hirota1">[40]</xref>
It is unknown by what mechanism EPO suppresses expansion of the Th17 cell subset in EAE animals. Since IL-6 has been reported to promote differentiation of naive CD4 T cells into Th17 cells in vitro, the level of IL-6 secretion by inflammatory cells could be playing a crucial role for in vivo development and expansion of Th17 cells [40]. Our in vitro studies demonstrated significantly reduced IL-6 levels in EPO treated MOG-T cell cultures, suggesting that down-regulation of Th17 by EPO could be a consequence of reduced IL-6 secretion. A less severe inflammatory environment in peripheral lymphoid tissue as well as in the CNS after EPO therapy may prevent significant Th17 migration into the CNS, thereby delaying disease onset and inducing less severe CNS pathology.
###end p 49
###begin p 50
###xml 877 881 877 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Chen1">[41]</xref>
###xml 883 887 883 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Stranges1">[42]</xref>
###xml 889 893 889 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Fujikado1">[43]</xref>
###xml 1407 1411 1404 1408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Brines2">[44]</xref>
###xml 564 568 <span type="species:ncbi:10090">mice</span>
###xml 655 659 <span type="species:ncbi:10090">mice</span>
The mechanism and precise signaling pathway by which EPO suppresses the immune response in the peripheral lymphoid tissues is also unknown. Since CD 11c expressing dendritic cells are pivotal in the control of developing immune responses, it may be that the EPO treatment induced massive 20-fold reduction in lymphoid dendritic cells coupled with marked down-regulation of MHC II expression on the surface of mononuclear cells in EAE is sufficient to block full development of the autoimmune process. This notion is supported by reports on 3 genetic conditions of mice where excessive DCs accumulate in the lymphoid tissues (DC-p35, CD11c-CRE Fas KI, and mice deficient in the immunoreceptor tyrosine-based inhibitor motif (Dcir)). These animals have greatly expanded dendritic cell populations; show exaggerated immune responses and subsequently develop systemic autoimmunity [41], [42], [43]. The classic EPO signaling pathway for erythropoiesis occurs through EPO ligand binding to EPO receptors and subsequent receptor dimerization, however there are recent reports claiming that EPO tissue protection is mediated by a different signaling pathway that involves binding to a hetero receptor composed of EPO receptor and the common beta receptor (betacR). The common beta receptor is used for IL-5, IL-3, and macrophage colony stimulating factor signaling and is upregulated during inflammatory responses [44] .
###end p 50
###begin p 51
###xml 270 274 270 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Li1">[14]</xref>
###xml 276 280 276 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Brines3">[45]</xref>
###xml 282 286 282 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Cuzzocrea1">[46]</xref>
###xml 370 376 <span type="species:ncbi:9606">humans</span>
Beneficial therapeutic effects of exogenously administered whole molecule EPO have been described in several animal models of neurologic injury, including occlusive cerebral vascular disease, acute brain trauma, epilepsy, as well as in both autoimmune arthritis and EAE [14], [45], [46]. However, application of even medium-term EPO therapy for most acute conditions in humans remains improbable because EPO therapy may overly stimulate erythropoiesis with the subsequent risk of thromboembolic complications. To overcome this concern, whole molecule EPO administration would have to be limited to very short term use.
###end p 51
###begin p 52
###xml 286 290 286 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Erbayraktar1">[47]</xref>
###xml 292 296 292 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Leist1">[48]</xref>
###xml 298 302 298 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Adembri1">[49]</xref>
###xml 547 551 547 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Yuan1">[50]</xref>
Other EPO molecular preparations, such as an asialo-form of EPO, carbamylated EPO (CEPO), or certain EPO mutants, have been reported to have protective effects in animals following experimental traumatic spinal cord injury or acute stroke without provoking an increase in red cell mass [47], [48], [49]. We have synthesized a library of low molecular weight cyclic EPO peptides that have been tested on the EAE animal model and we have identified a small domain that blocks paralysis in the acute EAE animal yet is devoid of hematopoietic effects [50]. This small domain appears to code for a region that contains most of the immuno/inflammatory modulating effects described in this report. Our evidence suggests that distinct functional and structural domain(s) co-exist within the whole molecule EPO, that retain tissue protective effects without manifesting hematopoietic side effects.
###end p 52
###begin p 53
###xml 208 212 208 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Crawford1">[51]</xref>
###xml 398 402 398 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-LeylandJones1">[52]</xref>
###xml 572 576 572 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Henke1">[53]</xref>
###xml 70 76 <span type="species:ncbi:9606">humans</span>
###xml 199 207 <span type="species:ncbi:9606">patients</span>
###xml 348 356 <span type="species:ncbi:9606">patients</span>
###xml 514 522 <span type="species:ncbi:9606">patients</span>
###xml 614 621 <span type="species:ncbi:9606">patient</span>
###xml 1026 1033 <span type="species:ncbi:9606">patient</span>
One of the surprising newly recognized consequences of EPO therapy in humans that has emerged over the past several years has been the unexpected negative effect of EPO therapy on survival in cancer patients [51]. A large clinical trial, the breast cancer erythropoietin survival trial (BEST) was terminated early because of an increased number of patients experiencing early demise in the EPO arm [52]. Poor survival was also reported in a randomized placebo controlled trial of Epoetin beta for the treatment of patients with head and neck cancer receiving radiotherapy [53]. The reason for the decreased cancer patient survival in these studies is unknown and enhanced tumor growth induced by signaling to EPO receptors growing on malignant cell surfaces has been suggested as one possible mechanism. The new observations described here in our report suggests another intriguing possibility that remains to be studied - could the immunomodulatory effects of EPO be contributing to suppressing immune function in the cancer patient?
###end p 53
###begin p 54
In conclusion, we investigated the mechanism behind the neuroprotective effects of EPO in classic autoimmune EAE animals and found that EPO has striking pleiotropic immunomodulatory effects on the peripheral lymphatic tissues as well as on the CNS target organ. EPO appears to restrain the overwhelming autoimmune response in MOG-immunized EAE animals and restores it to a more balanced immune status. Our studies suggest that multiple alterations including a reduction in total autoreactive T cells, DCs, MHC expression as well as an alteration in the balance between Th17 cells and expanded Treg cell populations within peripheral lymphoid tissue and CNS all contribute to EPO-mediated neuroprotection.
###end p 54
###begin title 55
Materials and Methods
###end title 55
###begin title 56
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 56
###begin p 57
###xml 32 36 <span type="species:ncbi:10090">mice</span>
C57BL/6 (8-10 weeks old) female mice were purchased from Charles River Laboratories and maintained in a conventional facility. The studies were conducted in accordance with the Animal Component of Research Protocol guidelines at the VA Hospital, East Orange, NJ, US.
###end p 57
###begin title 58
Animal Model of EAE
###end title 58
###begin p 59
###xml 103 108 95 100 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35&#8211;55</sub>
###xml 263 267 255 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Li1">[14]</xref>
###xml 666 670 654 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Li1">[14]</xref>
###xml 8 12 <span type="species:ncbi:10090">mice</span>
###xml 230 262 <span type="species:ncbi:419947">mycobacterium tuberculosis H37Ra</span>
###xml 356 376 <span type="species:ncbi:520">bordetella pertussis</span>
###xml 626 631 <span type="species:ncbi:10090">mouse</span>
C57BL/6 mice were immunized subcutaneously at the tail base with 100 microl (200 microg) of MOG peptide35-55 dissolved in distilled water and emulsified with an equal volume of complete Freund's adjuvant supplemented with 4 mg/ml mycobacterium tuberculosis H37Ra [14]. Immediately after immunization, animals received an intravenous injection of 200 ng of bordetella pertussis toxin (List Biological Laboratories, Campbell, CA) in 200 microl PBS. Animals were weighed daily and assessed for clinical signs of EAE by two independent observers. We used the same clinical EAE scoring system to assess neurological deficit in our mouse EAE model as previously described [14] .
###end p 59
###begin title 60
Treatment protocol
###end title 60
###begin p 61
EPO (Epoetin Alfa, Ortho Biotech products, LP) in 2,000 U/ml vial stock was stored at 4degreesC. Administration of EPO was initiated either at the time of immunization or delayed until day 7 post-immunization. Animals were treated with intravenous EPO (5000 U/kg/dayx3 days followed by 1000 U/kg/dayx3 days) in freshly prepared saline or sham treated for 6 days with an equal volume of saline.
###end p 61
###begin title 62
Mononuclear cell suspensions prepared from peripheral lymphoid and CNS tissue
###end title 62
###begin p 63
###xml 388 392 388 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Korn1">[54]</xref>
###xml 732 736 732 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Korn1">[54]</xref>
###xml 534 538 <span type="species:ncbi:10090">mice</span>
At various time-points (before disease onset, at peak disease, and during recovery or later phases), animals were sacrificed, their draining inguinal lymph nodes and spleen removed for erythrocyte-depleted single-cell suspension preparations. The total MNCs were quantified subsequently. Mononuclear cells from the spinal cord were isolated following a published protocol by Korn T et al [54]. In brief, after perfusion through the left ventricle with cold PBS the pooled spinal cords from 6 animals were collected from MOG-immunized mice at each time-point. The spinal cords were cut into small pieces, minced, and passed through a tissue strainer and the mononuclear infiltrate obtained by purification through a Percoll gradient [54].
###end p 63
###begin title 64
Antibodies for flow cytometry
###end title 64
###begin p 65
###xml 25 30 <span type="species:ncbi:10090">mouse</span>
Cell surface staining of mouse single cell suspensions was obtained with mAbs directed against CD3, CD4, CD8, MHC class I, II and CD11c (BD PharMingen, San Diego, CA). Flow cytometry was performed on a BD FACScan machine (BD Biosciences). For intracellular IL-17 or Foxp3 staining, cells were first reacted with FITC-anti-CD4 or FITC-anti-CD4/APC-anti-CD25 (eBioscience, San Diego), then washed, fixed and permeabilized following the manufacturer's recommendations. The PE conjugated anti-Foxp3 or anti-IL-17 Mab was subsequently added. The samples were subjected to flow cytometry after multiple washings. Flow cytometry data was analyzed using CellQuest software and the Flowjo analysis program.
###end p 65
###begin title 66
EPO effects on MOG-EAE-specific T cells in tissue culture
###end title 66
###begin p 67
###xml 58 63 58 63 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35&#8211;55</sub>
###xml 160 164 160 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Yuan2">[55]</xref>
###xml 297 302 297 302 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35&#8211;55</sub>
###xml 688 693 688 693 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">44&#8211;54</sub>
###xml 698 699 698 699 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 714 721 714 721 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">366&#8211;374</sub>
###xml 726 727 726 727 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 833 834 833 834 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 1204 1208 1204 1208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001924-Sun2">[19]</xref>
###xml 28 32 <span type="species:ncbi:10090">mice</span>
###xml 139 142 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 823 828 <span type="species:ncbi:10090">mouse</span>
MNCs were obtained from EAE mice spleens 5-7 days post MOG35-55 immunization. T cells were isolated from the single cell suspensions using MAC pan-T cell beads [55]. The MOG-specific T cells were then enriched by repeated stimulation with syngeneic splenic antigen presenting cells pulsed with MOG35-55 peptide antigen. To determine the biological effect of EPO on antigen specific T cells and their secreted cytokines, the in vitro enriched MOG-specific T cells were washed three times with cold PBS and then incubated with log dilutions of EPO (1, 10 and 100 U/ml) in culture medium (RPMI1640 supplemented with 10% FCS) for 48-72 hrs. Control cells were incubated with medium alone. MOG44-54/H2-Db and control NP366-374/H2-Db dimers were freshly prepared by adding the truncated peptides to a recombinant soluble dimeric mouse H-2Db:IgG1 fusion protein (BD Pharmingen, San Diego, CA). Cell culture supernatants were collected from each experimental sample well for cytokine profile analysis (below). Flow cytometry of either EPO treated cells or control cells was performed using dual-color staining with peptide dimer complexes and anti-CD3 mAb to determine the level of MOG specific effector T cells [19].
###end p 67
###begin title 68
Effect of EPO on cytokine levels in MOG-EAE specific T cell cultures
###end title 68
###begin p 69
Luminex technology was used to detect multiple cytokines and chemokines simultaneously within the pre-treated EAE T cell culture supernatants (above). Commercial kits (Upstate, Lake Placid, NY) containing multi-cytokine beads (IL-1beta, IL-2, IL-4, IL-5, IL-6, IL-10, GM-CSF, IL-12, TNFalpha and IFN-gamma) were run with their enclosed buffers and standards, following directions from the manufacturer. To obtain concentration values, mean fluorescence intensities from the bead combinations were analyzed by the MasterPlex QT quantification software.
###end p 69
###begin title 70
Immunohistochemistry
###end title 70
###begin p 71
Spinal cords were obtained from sham or EPO treated MOG-EAE animals. Immunohistochemical staining for intracellular Foxp3 was performed using biotinylated Foxp3 antibody (eBioscience, San Diego, CA) and an avidin-biotin immunoperoxidase detection system on paraffin-embedded spinal cord sections.
###end p 71
###begin title 72
Statistical analysis
###end title 72
###begin p 73
Data are presented as the mean+/-SEM. The Mann-Whitney U test was used to determine the significance of the intergroup difference in EAE clinical scores and duration of maximum neurological deficit. The composite data was analyzed by the Kruskal-Wallis one-way analysis of variance. Values of p<0.05 were considered significant.
###end p 73
###begin p 74
The authors wish to thank Joseph Menonna for his excellent technical support.
###end p 74
###begin title 75
References
###end title 75
###begin article-title 76
Selection of the T cell repertoire.
###end article-title 76
###begin article-title 77
Negative selection of T cells occurs throughout thymic development.
###end article-title 77
###begin article-title 78
Involvement of avidity for major histocompatibility complex in homeostasis of naive and memory T cells.
###end article-title 78
###begin article-title 79
T lymphocyte tolerance: from thymic deletion to peripheral control mechanisms.
###end article-title 79
###begin article-title 80
Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells.
###end article-title 80
###begin article-title 81
Differentiation and function of Th17 T cells.
###end article-title 81
###begin article-title 82
IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis.
###end article-title 82
###begin article-title 83
A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis.
###end article-title 83
###begin article-title 84
Autoimmune inflammation from the Th17 perspective.
###end article-title 84
###begin article-title 85
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.
###end article-title 85
###begin article-title 86
Cutting edge: CD4+CD25+ regulatory T cells contribute to gender differences in susceptibility to experimental autoimmune encephalomyelitis.
###end article-title 86
###begin article-title 87
Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis.
###end article-title 87
###begin article-title 88
Animal models.
###end article-title 88
###begin article-title 89
Beneficial effect of erythropoietin on experimental allergic encephalomyelitis.
###end article-title 89
###begin article-title 90
The CD8 T cell in multiple sclerosis: suppressor cell or mediator of neuropathology?
###end article-title 90
###begin article-title 91
Myelin-specific CD8 T cells in the pathogenesis of experimental allergic encephalitis and multiple sclerosis.
###end article-title 91
###begin article-title 92
Specificity, magnitude, and kinetics of MOG-specific CD8+ T cell responses during experimental autoimmune encephalomyelitis.
###end article-title 92
###begin article-title 93
###xml 96 100 <span type="species:ncbi:10090">mice</span>
Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice.
###end article-title 93
###begin article-title 94
Encephalitogenic activity of truncated myelin oligodendrocyte glycoprotein (MOG) peptides and their recognition by CD8+ MOG-specific T cells on oligomeric MHC class I molecules.
###end article-title 94
###begin article-title 95
Cytokine shifts and tolerance in experimental autoimmune encephalomyelitis.
###end article-title 95
###begin article-title 96
###xml 71 75 <span type="species:ncbi:10090">mice</span>
The cytokine signature of MOG-specific CD4 cells in the EAE of C57BL/6 mice.
###end article-title 96
###begin article-title 97
Gamma delta T cell regulation of IFN-gamma production by central nervous system-infiltrating encephalitogenic T cells: correlation with recovery from experimental autoimmune encephalomyelitis.
###end article-title 97
###begin article-title 98
Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise.
###end article-title 98
###begin article-title 99
Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis.
###end article-title 99
###begin article-title 100
Erythropoietin and erythropoietin receptor expression after experimental spinal cord injury encourages therapy by exogenous erythropoietin.
###end article-title 100
###begin article-title 101
Foxp3 in control of the regulatory T cell lineage.
###end article-title 101
###begin article-title 102
###xml 48 54 <span type="species:ncbi:10090">murine</span>
Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis.
###end article-title 102
###begin article-title 103
###xml 80 84 <span type="species:ncbi:10090">mice</span>
Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice.
###end article-title 103
###begin article-title 104
An interferon-gamma-producing Th1 subset is the major source of IL-17 in experimental autoimmune encephalitis.
###end article-title 104
###begin article-title 105
The role of CD8(+) T cells in multiple sclerosis and its animal models.
###end article-title 105
###begin article-title 106
A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis.
###end article-title 106
###begin article-title 107
The role of CD8+ T-cells in lesion formation and axonal dysfunction in multiple sclerosis.
###end article-title 107
###begin article-title 108
GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis.
###end article-title 108
###begin article-title 109
Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis.
###end article-title 109
###begin article-title 110
Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self.
###end article-title 110
###begin article-title 111
Myelin proteolipid protein-specific CD4+CD25+ regulatory cells mediate genetic resistance to experimental autoimmune encephalomyelitis.
###end article-title 111
###begin article-title 112
Epicutaneous immunization with autoantigenic peptides induces T suppressor cells that prevent experimental allergic encephalomyelitis.
###end article-title 112
###begin article-title 113
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis.
###end article-title 113
###begin article-title 114
###xml 157 161 <span type="species:ncbi:10090">mice</span>
Kinetics and organ distribution of IL-17-producing CD4 cells in proteolipid protein 139-151 peptide-induced experimental autoimmune encephalomyelitis of SJL mice.
###end article-title 114
###begin article-title 115
T cell self-reactivity forms a cytokine milieu for spontaneous development ofIL-17+ Th cells that cause autoimmune arthritis.
###end article-title 115
###begin article-title 116
Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis.
###end article-title 116
###begin article-title 117
Elimination of antigen-presenting cells and autoreactive T cells by Fas contributes to prevention of autoimmunity.
###end article-title 117
###begin article-title 118
###xml 61 65 <span type="species:ncbi:10090">mice</span>
Dcir deficiency causes development of autoimmune diseases in mice due to excess expansion of dendritic cells.
###end article-title 118
###begin article-title 119
Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor.
###end article-title 119
###begin article-title 120
Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury.
###end article-title 120
###begin article-title 121
###xml 81 86 <span type="species:ncbi:10090">mouse</span>
Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse.
###end article-title 121
###begin article-title 122
Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo.
###end article-title 122
###begin article-title 123
Derivatives of erythropoietin that are tissue protective but not erythropoietic.
###end article-title 123
###begin article-title 124
Carbamylated erythropoietin derivative is neuroprotective in an experimental model of traumatic brain injury.
###end article-title 124
###begin article-title 125
Novel small erythropoietin-derived peptides that retain CNS neuroprotective effects while lacking hematopoietic activity.
###end article-title 125
###begin article-title 126
Erythropoietin: high profile, high scrutiny.
###end article-title 126
###begin article-title 127
###xml 75 83 <span type="species:ncbi:9606">patients</span>
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.
###end article-title 127
###begin article-title 128
Do erythropoietin receptors on cancer cells explain unexpected clinical findings?
###end article-title 128
###begin article-title 129
Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation.
###end article-title 129
###begin article-title 130
Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers.
###end article-title 130
###begin p 131
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 131
###begin p 132
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by a VA Merit Review, the Segal Foundation, New Jersey State Commission on Cancer Research and the National MS Society.
###end p 132

